By Dr Kevin Ni

Conference Presentations

Chang L; Peter G; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley J; Li Y; Hao J, 2012, 'Epithelial mesenchymal transition (EMT) is involved in the prostate cancer radiation resistance.', presented at IPOS 14th World Congress and COSA's 39th Annual Scientific Meeting, Brisbane, Australia, 13 November 2012 - 15 November 2012

Ni K, 2012, 'EpCAM (CD326) and CD44 variants are biomarkers associated with prostate cancer metastasis and progression.', presented at The St George & Sutherland Medical Research Symposium, 11 October 2012 - 11 October 2012

Conference Abstracts

Katelaris A; Canagasingham A; Ni J; Deshpande N; Malouf D; Bucci J; Thompson J; Bai X; Pang B; Zhu Y; Wilkins M; Graham P; Li Y, 2022, 'Isolation of exosomal microRNA to serve as a diagnostic biomarker for prostate cancer: A provisional analysis of 12 patients', in BJU INTERNATIONAL, WILEY, AUSTRALIA, Gold Coast, Vol. 129, pp. 140 - 140, presented at Annual Scientific Meeting of the Urological-Society-of-Australia-and-New Zealand, AUSTRALIA, Gold Coast, 25 June 2022 - 28 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000808481200227&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bai X; Feng X; Ni J; Beretov J; Deng J; Zhu Y; Graham P; Li Y, 2019, 'CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4754

Ni J; Cozzi P; Beretov J; Bucci J; Graham P; Li Y, 2017, 'Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models', in Annals of Oncology, Vol. 28, pp. x78 - x79, http://dx.doi.org/10.1093/annonc/mdx662.006

Hao J; Graham P; Chang L; Ni J; Beretov J; Deng J; Bucci J; Cozzi P; Li Y, 2015, 'Combination of LBH589 and radiotherapy overcomes radioresistance in radioresistant prostate cancer cells in vitro and animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 33 - 34, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ni J; Cozzi P; Hao J; Beretov J; Chang L; Deng J; Duan W; Graham P; Bucci J; Li Y, 2015, 'Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer chemo-/radio-resistance in cell lines in vitro and in animal models in vivo', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Cairns, Vol. 116, pp. 31 - 31, presented at 2nd Prostate Cancer World Congress (PCWC), AUSTRALIA, Cairns, 17 August 2015 - 21 August 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359254200087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hao J; Graham PH; Chang L; Ni J; Wasinger V; Beretov J; Bucci J; Cozzi P; Li Y, 2015, 'Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-2001

Ni K, 2014, 'CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro.', in CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/β-catenin signalling pathways in vitro., presented at AACR 2014

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., presented at The St George & Sutherland Medical Research Symposium

Ni K, 2013, 'CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression.', in CD44 variant 6 is a biomarker associated with prostate cancer metastasis and progression., presented at LOWY cancer symposium

Ni K, 2012, 'Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy.', in Over-expression of EpCAM (CD326) and CD44 variants in human prostate cancer cells are potential therapeutic targets for targeted therapy., presented at 13th Australasian Prostate Cancer Conference

Back to profile page